$SONN
Sonnet Biotherapeutics Holdings Inc Stock $sonn

$sonn Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000149315224006308 Filed on February 14, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2022 Q4
Revenue		$18.63K	$37.26K
YoY Change		-50.0%	-71.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.701M	$653.5K	$1.904M
YoY Change	-9.73%	-65.67%	-8.43%
% of Gross Profit
Research & Development	$2.167M	$644.0K	$3.746M
YoY Change	-43.21%	-82.81%	-12.19%
% of Gross Profit
Depreciation & Amortization	$3.210K	$3.211K	$3.211K
YoY Change	0.0%	0.0%	0.03%
% of Gross Profit
Operating Expenses	$3.869M	$1.297M	$5.650M
YoY Change	-32.14%	-77.03%	-10.96%
Operating Profit	-$3.869M	-$1.279M	-$5.612M
YoY Change	-31.71%	-77.21%	-9.7%
Interest Expense	-$93.96K	$110.4K	$70.25K
YoY Change	3985.22%	57.1%	402.86%
% of Operating Profit
Other Income/Expense, Net	$4.328M
YoY Change
Pretax Income	$365.4K	-$1.169M	-$5.542M
YoY Change	-106.45%	-78.92%	-10.62%
Income Tax
% Of Pretax Income
Net Earnings	$365.4K	-$1.169M	-$5.542M
YoY Change	-106.45%	-78.92%	-10.62%
Net Earnings / Revenue		-6273.54%	-14876.24%
Basic Earnings Per Share	$0.08	-$0.31	-$0.80
Diluted Earnings Per Share	$0.07	-$0.31	-$0.80
COMMON SHARES
Basic Shares Outstanding	3.070M shares	3.070M shares	7.934M shares
Diluted Shares Outstanding	4.886M shares	3.798M shares	314.5K shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.786M	$3.021M	$1.701M
YoY Change	-66.76%	77.67%	-91.24%
Cash & Equivalents	$3.786M	$3.021M	$1.701M
Short-Term Investments
Other Short-Term Assets	$1.059M	$1.408M	$1.561M
YoY Change	-12.39%	-9.79%	32.97%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$5.223M	$4.624M	$4.598M
YoY Change	-59.96%	0.56%	-77.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$26.94K	$30.16K	$43.00K
YoY Change	-32.28%	-29.87%	-72.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$484.8K	$491.9K	$60.34K
YoY Change		715.15%
Total Long-Term Assets	$686.4K	$713.9K	$344.7K
YoY Change	158.54%	107.12%	119.81%
TOTAL ASSETS
Total Short-Term Assets	$5.223M	$4.624M	$4.598M
Total Long-Term Assets	$686.4K	$713.9K	$344.7K
Total Assets	$5.909M	$5.338M	$4.943M
YoY Change	-55.61%	7.99%	-76.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.752M	$1.655M	$4.574M
YoY Change	-61.06%	-63.81%	116.54%
Accrued Expenses	$1.012M	$998.9K	$3.538M
YoY Change	-67.48%	-71.77%	91.77%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$750.00
YoY Change	-100.0%	-100.0%	0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.765M	$2.654M	$8.293M
YoY Change	-64.44%	-67.99%	90.89%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$90.45K	$111.0K	$186.7K
YoY Change	-46.46%	-40.56%	3633.8%
Total Long-Term Liabilities	$90.45K	$111.0K	$186.7K
YoY Change	-46.46%	-40.56%	3633.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.765M	$2.654M	$8.293M
Total Long-Term Liabilities	$90.45K	$111.0K	$186.7K
Total Liabilities	$2.855M	$2.765M	$8.480M
YoY Change	-64.05%	-67.39%	94.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$111.0M	-$111.4M	-$96.95M
YoY Change	8.21%	14.91%
Common Stock	$311.00	$307.00	$796.00
YoY Change	-84.83%	-61.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.054M	$2.572M	-$3.537M
YoY Change
Total Liabilities & Shareholders Equity	$5.909M	$5.338M	$4.943M
YoY Change	-55.61%	7.99%	-76.17%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2022 Q4
OPERATING ACTIVITIES
Net Income	$365.4K	-$1.169M	-$5.542M
YoY Change	-106.45%	-78.92%	-10.62%
Depreciation, Depletion And Amortization	$3.210K	$3.211K	$3.211K
YoY Change	0.0%	0.0%	0.03%
Cash From Operating Activities	$723.8K	-$3.092M	-$5.915M
YoY Change	-115.41%	-47.73%	-26.9%
INVESTING ACTIVITIES
Capital Expenditures	$0.00		$0.00
YoY Change	-100.0%		-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	41.00K	$3.839M	$4.563M
YoY Change	-99.72%	-15.87%
NET CHANGE
Cash From Operating Activities	723.8K	-$3.092M	-$5.915M
Cash From Investing Activities	0.000
Cash From Financing Activities	41.00K	$3.839M	$4.563M
Net Change In Cash	764.8K	$747.1K	-$1.352M
YoY Change	-92.11%	-155.25%
FREE CASH FLOW
Cash From Operating Activities	$723.8K	-$3.092M	-$5.915M
Capital Expenditures	$0.00		$0.00
Free Cash Flow	$723.8K		-$5.915M
YoY Change	-114.6%		-25.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2023Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q4	dei	Entity Central Index Key EntityCentralIndexKey	0001106838
CY2023Q4	SONN	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
CY2023Q4	SONN	Stock Issued During Period Value Net Share Settlement Of Warrants StockIssuedDuringPeriodValueNetShareSettlementOfWarrants		usd
CY2022Q4	SONN	Stock Issued During Period Value Net Share Settlement Of Warrants StockIssuedDuringPeriodValueNetShareSettlementOfWarrants		usd
CY2022Q4	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
CY2023Q4	SONN	Deferred Offering Costs Charged Against Proceeds From Sale Of Common Stock DeferredOfferingCostsChargedAgainstProceedsFromSaleOfCommonStock		usd
CY2023Q4	dei	Document Type DocumentType	10-Q
CY2023Q4	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q4	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023Q4	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q4	dei	Entity File Number EntityFileNumber	001-35570
CY2023Q4	dei	Entity Registrant Name EntityRegistrantName	SONNET BIOTHERAPEUTICS HOLDINGS, INC.
CY2023Q4	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q4	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-2932652
CY2023Q4	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Overlook Center
CY2023Q4	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 102
CY2023Q4	dei	Entity Address City Or Town EntityAddressCityOrTown	Princeton
CY2023Q4	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023Q4	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08540
CY2023Q4	dei	City Area Code CityAreaCode	(609)
CY2023Q4	dei	Local Phone Number LocalPhoneNumber	375-2227
CY2023Q4	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023Q4	dei	Trading Symbol TradingSymbol	SONN
CY2023Q4	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q4	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q4	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q4	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q4	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q4	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q4	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3069516	shares
CY2023Q4	us-gaap	Cash Cash	3021392	usd
CY2023Q3	us-gaap	Cash Cash	2274259	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1408280	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1677396	usd
CY2023Q4	SONN	Incentive Tax Receivable Current IncentiveTaxReceivableCurrent	194111	usd
CY2023Q3	SONN	Incentive Tax Receivable Current IncentiveTaxReceivableCurrent	786574	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4623783	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	4738229	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30155	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33366	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	176926	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	193689	usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	15000	usd
CY2023Q3	us-gaap	Deferred Costs DeferredCosts	49988	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	491862	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	414206	usd
CY2023Q4	us-gaap	Assets Assets	5337726	usd
CY2023Q3	us-gaap	Assets Assets	5429478	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1655390	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2201999	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	923191	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3230922	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	75730	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	73048	usd
CY2023Q3	us-gaap	Deferred Income Current DeferredIncomeCurrent	18626	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2654311	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5524595	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	110956	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	130863	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2765267	usd
CY2023Q3	us-gaap	Liabilities Liabilities	5655458	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3069516	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3069516	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1750426	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1750426	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	307	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	175	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	113984414	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	110017598	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111412262	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110243753	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2572459	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-225980	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5337726	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5429478	usd
CY2023Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18626	usd
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37255	usd
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	644042	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3745940	usd
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	653455	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1903709	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	1297497	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	5649649	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1278871	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-5612394	usd
CY2023Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	110362	usd
CY2022Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	70252	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-1168509	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-5542142	usd
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-17.62
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-17.62
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3797753	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3797753	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	314472	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	314472	shares
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-225980	usd
CY2023Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3916943	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	50005	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-1168509	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2572459	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2538719	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2538719	usd
CY2022Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4452012	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	91617	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-5542142	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3537232	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3537232	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-1168509	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-5542142	usd
CY2023Q4	SONN	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	12000	usd
CY2022Q4	SONN	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	100000	usd
CY2023Q4	us-gaap	Depreciation Depreciation	3211	usd
CY2022Q4	us-gaap	Depreciation Depreciation	3211	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	16763	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	15223	usd
CY2023Q4	us-gaap	Share Based Compensation ShareBasedCompensation	50005	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	91617	usd
CY2023Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-269116	usd
CY2022Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-82673	usd
CY2023Q4	SONN	Increase Decrease In Incentive Tax Receivable IncreaseDecreaseInIncentiveTaxReceivable	-592463	usd
CY2022Q4	SONN	Increase Decrease In Incentive Tax Receivable IncreaseDecreaseInIncentiveTaxReceivable	619118	usd
CY2023Q4	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	77656	usd
CY2023Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-465735	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-375540	usd
CY2023Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2287544	usd
CY2022Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	383362	usd
CY2023Q4	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-17225	usd
CY2022Q4	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-17201	usd
CY2023Q4	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-18626	usd
CY2022Q4	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-37255	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3091737	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5915170	usd
CY2023Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3838870	usd
CY2022Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4562895	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3838870	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4562895	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	747133	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1352275	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2274259	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3052879	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3021392	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1700604	usd
CY2023Q4	SONN	In Process Research And Development In Accrued Expenses InProcessResearchAndDevelopmentInAccruedExpenses	12000	usd
CY2022Q4	SONN	In Process Research And Development In Accrued Expenses InProcessResearchAndDevelopmentInAccruedExpenses	261250	usd
CY2023Q4	SONN	Offering Costs In Accounts Payable And Accrued Expenses OfferingCostsInAccountsPayableAndAccruedExpenses	15000	usd
CY2022Q4	SONN	Offering Costs In Accounts Payable And Accrued Expenses OfferingCostsInAccountsPayableAndAccruedExpenses	138878	usd
CY2022Q4	SONN	Deferred Offering Costs Charged Against Proceeds From Sale Of Common Stock DeferredOfferingCostsChargedAgainstProceedsFromSaleOfCommonStock	32340	usd
CY2023Q4	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_803_eus-gaap--NatureOfOperations_zL7BSZbPW977" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_82E_zeFqqQLtjF2h">Organization and Description of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Description of business</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonnet BioTherapeutics, Inc. (“Prior Sonnet”) was incorporated as a New Jersey corporation on April 6, 2015. Prior Sonnet completed a merger with publicly-held Chanticleer Holdings, Inc. (“Chanticleer”) on April 1, 2020. After the merger, Chanticleer changed its name to Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”). Sonnet is a clinical stage, oncology-focused biotechnology company with a proprietary platform for innovating biologic medicines with single or bifunctional action. Known as F<sub>H</sub>AB™ (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (“HSA”) for transport to target tissues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonnet’s lead proprietary asset, SON-1010, is a fully human single chain version of Interleukin 12 (“IL-12”), covalently linked to the F<sub>H</sub>AB construct, for which Sonnet is pursuing clinical development in solid tumor indications, including ovarian cancer, non-small cell lung cancer and head and neck cancer. In March 2022, the FDA cleared Sonnet’s Investigational New Drug (“IND”) application for SON-1010. This allowed the Company to initiate a U.S. clinical trial (SB101) in oncology patients with solid tumors during the second calendar quarter of 2022. In September 2021, the Company created a wholly-owned Australian subsidiary, SonnetBio Pty Ltd (“Subsidiary”), for the purpose of conducting certain clinical trials in that country. Sonnet received approval and initiated an Australian clinical study (SB102) of SON-1010 in healthy volunteers during the third calendar quarter of 2022. Interim safety and tolerability data from the SB101 and SB102 studies were reported in April 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2023, Sonnet announced a collaboration agreement with Roche for the clinical evaluation of SON-1010 with atezolizumab (Tecentriq®). The companies have entered into a Master Clinical Trial and Supply Agreement (“MCSA”), along with ancillary Quality and Safety Agreements, to study the safety and efficacy of the combination of SON-1010 and atezolizumab in a platinum-resistant ovarian cancer (“PROC”) patient setting. Furthermore, the companies will provide SON-1010 and atezolizumab, respectively, for use in the Phase 1b/Phase 2a combination safety, dose-escalation, and efficacy study (SB221). Part 1 of this 2-part study was approved in June 2023 by the local Human Research Ethics Committee in Australia under CT-2023-CTN-01399-1 and the Therapeutic Goods Administration has been notified. In August 2023, the FDA accepted the IND for SON-1010 in this indication. The trial consists of a modified 3+3 dose-escalation design in Part 1 to establish the maximum tolerated dose (“MTD”) of SON-1010 with a fixed dose of atezolizumab. Clinical benefit in PROC will be confirmed in an expansion group to establish the recommended Phase 2 dose (“RP2D”). Part 2 of the study will then investigate SON-1010 monotherapy, its use in combination with atezolizumab, or the standard of care (“SOC”) for PROC in a randomized comparison to show proof-of-concept (“POC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As part of the ongoing cost-cutting evaluations, all antiviral development with SON-1010 has been suspended.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company acquired the global development rights to its most advanced compound, SON-080, a fully human version of Interleukin 6 (“IL-6”), in April 2020 through its acquisition of the outstanding shares of Relief Therapeutics SA. Sonnet is advancing SON-080 in target indications of Chemotherapy-Induced Peripheral Neuropathy (“CIPN”) and Diabetic Peripheral Neuropathy (“DPN”). Sonnet received approval to initiate an ex-U.S. Phase 1b/2a study with SON-080 in CIPN during the third quarter of 2022. The Data Safety Monitoring Board (“DSMB”) overseeing the study is expected to meet during the first calendar quarter of 2024. Following the completion of the DSMB review, Sonnet anticipates announcing initial safety data from the CIPN study. Pursuant to a license agreement the Company entered into with New Life Therapeutics Pte, Ltd. (“New Life”) of Singapore in May 2021, Sonnet and New Life will be jointly responsible for developing SON-080 in DPN. The objective will be to analyze the data and to consider initiating a Phase 2 study once the CIPN safety data has been evaluated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sonnet BioTherapeutics Holdings, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Unaudited Interim Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SON-1210 (IL12-F<sub>H</sub>AB-IL15), Sonnet’s lead bifunctional construct, combines F<sub>H</sub>AB with fully human IL-12 and fully human Interleukin 15 (“IL-15”). This compound is being developed for solid tumor indications, including colorectal cancer. In February 2023, the Company announced the successful completion of two IND-enabling toxicology studies with <span style="background-color: white">SON-1210 in non-human primates. Sonnet is prepared to initiate the regulatory authorization process for SON-1210 to begin clinical development pending the outcome of any partnering activity.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">SON-1410 (IL18-F</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sub>H</sub><span style="background-color: white">AB-IL12) is a <span style="background-color: white">bifunctional</span> combination of Interleukin 18 (“IL-18”) and IL-12 for solid tumor cancers. Cell line development and process development are ongoing, with early experimental drug supply suitable for formulation and analytical method development activities. After some delays in 2023, activities will continue through 2024 with the potential to generate a drug suitable for preclinical studies and subsequent human studies.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has completed sequence confirmation for SON-3015 (anti-IL6-F<sub>H</sub>AB-anti-TGFβ). Early stage bifunctional drug has been generated and is being stored for future use with <i>in vivo</i> studies in mice. Sonnet has elected to place the SON-3015 development program on hold for expense reduction purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has incurred recurring losses and negative cash flows from operations since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates. The Company believes its cash of $<span id="xdx_90F_eus-gaap--Cash_iI_pn5n6_c20231231_zHsxazOE0Cd3" title="Cash">3.0</span> million at December 31, 2023 will fund the Company’s projected operations into March 2024. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying unaudited interim consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The unaudited interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recently executed an agreement to sell $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231_zKRoFe3HLpYh" title="Net operating losses">4.8</span> million of its New Jersey state net operating losses through the Technology Business Tax Certificate Transfer Program (the “Program”) for expected net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromOperatingActivities_pn5n6_c20231001__20231231_z20hHV02qZP4" title="Proceeds from sale of net operating losses">4.3</span> million, subject to final approval by the state. Substantial additional financing will be needed by the Company to fund its operations. The Company plans to secure additional capital in the future through equity or debt financings, partnerships, collaborations, or other sources to carry out the Company’s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company’s product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company’s product candidates, length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will materially affect the Company’s financial condition and future operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations since inception have consisted primarily of organizing the Company, securing financing, developing technologies through research and development and conducting preclinical and clinical studies. The Company faces risks associated with companies whose products are in development. These risks include the need for additional financing to complete its research and development, achieving its research and development objectives, defending its intellectual property rights, recruiting and retaining skilled personnel, and dependence on key members of management.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sonnet BioTherapeutics Holdings, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Unaudited Interim Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q4	us-gaap	Cash Cash	3000000.0	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	4800000	usd
CY2023Q4	us-gaap	Proceeds From Operating Activities ProceedsFromOperatingActivities	4300000	usd
CY2023Q4	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zirksR2cVszb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zQh7oQAak6Ji">Use of estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited interim consolidated financial statements include the accrual of research and development expenses. Estimates and assumptions are periodically reviewed in-light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from management’s estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Refund Received Related To Revenue From Different Year Year Revenue Recognized RefundReceivedRelatedToRevenueFromDifferentYearYearRevenueRecognized	The cash refund is available to eligible companies with annual aggregate revenues of less than $20.0 million (Australian) during the reimbursable period.
CY2023Q4	SONN	Cash Refund Expected To Be Received CashRefundExpectedToBeReceived	200000	usd
CY2022Q4	SONN	Cash Refund Expected To Be Received CashRefundExpectedToBeReceived	300000	usd
CY2023Q4	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	800000	usd
CY2023Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-22 reverse stock split
CY2023Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6447803	shares
CY2022Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	190262	shares
CY2023Q4	SONN	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	141636	usd
CY2023Q3	SONN	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	2091196	usd
CY2023Q4	SONN	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	564674	usd
CY2023Q3	SONN	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	913145	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	213912	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	224031	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2969	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2550	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	923191	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3230922	usd
CY2023Q4	SONN	Increase Decrease In Research And Development Expenses IncreaseDecreaseInResearchAndDevelopmentExpenses	1000000.0	usd
CY2023Q4	SONN	Increase Decrease In General And Administrative Expenses IncreaseDecreaseInGeneralAndAdministrativeExpenses	900000	usd
CY2023Q4	us-gaap	Collaborative Arrangement Rights And Obligations CollaborativeArrangementRightsAndObligations	New Life is also obligated to pay a non-refundable deferred license fee of an additional $1.0 million at the time of the satisfaction of certain milestones, as well as potential additional milestone payments to the Company of up to $19.0 million subject to the achievement of certain development and commercialization milestones. In addition, during the Royalty Term (as defined below), New Life is obligated to pay the Company tiered double-digit royalties ranging from 12% to 30% based on annual net sales of Products in the Exclusive Territory. The “Royalty Term” means, on a Product-by-Product and a country-by-country basis in the Exclusive Territory, the period commencing on the date of the first commercial sale (subject to certain conditions) of such Product in such country in the Exclusive Territory and continuing until New Life ceases commercialization of such Product in the DIPN Field
CY2023Q4	SONN	Performanceobligation Performanceobligation	1000000.0	usd
CY2023Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18626	usd
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37255	usd
CY2022Q4	SONN	Warrant Expirations WarrantExpirations	242	shares
CY2023Q4	us-gaap	Share Based Compensation ShareBasedCompensation	50005	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	91617	usd
CY2022Q3	SONN	Excise Tax ExciseTax	0.01	pure

Files In Submission

Name	View Source	Status
0001493152-24-006308-index-headers.html	Edgar Link	pending
0001493152-24-006308-index.html	Edgar Link	pending
0001493152-24-006308.txt	Edgar Link	pending
0001493152-24-006308-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sonn-20231231.xsd	Edgar Link	pending
sonn-20231231_def.xml	Edgar Link	unprocessable
sonn-20231231_pre.xml	Edgar Link	unprocessable
sonn-20231231_lab.xml	Edgar Link	unprocessable
sonn-20231231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SONN
Sonnet Biotherapeutics Holdings Inc Stock $sonn

2024 Q1 Form 10-Q Financial Statement

#000149315224006308 Filed on February 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SONN Sonnet Biotherapeutics Holdings Inc Stock $sonn

2024 Q1 Form 10-Q Financial Statement

#000149315224006308 Filed on February 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SONN
Sonnet Biotherapeutics Holdings Inc Stock $sonn